Remington's Pharmaceutical Sciences

Control of the second se

Eighteemth Edition



Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by Joseph P Remington Estate

Copyright 1948, 1951, by The Philadelphia College of Pharmacy and Science

Copyright © 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, by The Philadelphia College of Pharmacy and Science

All Rights Reserved

Library of Congress Catalog Card No. 60-53334 ISBN 0-912734-04-3

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

NOTICE—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

Printed in the United States of America by the Mack Printing Company, Easton, Pennsylvania



Table of Contents

	Part 1 Orientation		44 45	Cholinomimetic Drugs	889
1	Scope	3		Drugs	898
2	Evolution of Pharmacy	8	46	Antimuscarinic and Antispasmodic Drugs	907
3	Ethics	20	47	Skeletal Muscle Relaxants	916
4	The Practice of Community Pharmacy	28	48	Diuretic Drugs	929
5	Opportunities for Pharmacists in the Pharmaceuti-		49	Uterine and Antimigraine Drugs	943
	cal Industry	33	50	Hormones	948
6	Pharmacists in Government	38	51	Vitamins and Other Nutrients	1002
7	Drug Information	49	52	Enzymes	1035
8	Research	60	53	General Anesthetics	1039
			54	Local Anesthetics	1048
	Part 2 Pharmaceutics		55	Sedatives and Hypnotics	1057
			56	Antiepileptics	1072
9	Metrology and Calculation	69	57	Psychopharmacologic Agents	1082
10	Statistics	104	58	Analgesics and Antipyretics	1097
11	Computer Science	138	59	Histamine and Antihistamines	1123
12	Calculus	145	60	Central Nervous System Stimulants	1132
13	Molecular Structure, Properties and States of		61	Antineoplastic and Immunosuppressive Drugs	1138
	Matter	158	62	Antimicrobial Drugs	1163
14	Complex Formation	182	63	Parasiticides	1242
15	Thermodynamics	197	64	Pesticides	1249
16	Solutions and Phase Equilibria	207	65	Diagnostic Drugs	1272
17	Ionic Solutions and Electrolytic Equilibria	228	66	Pharmaceutical Necessities	1286
18	Reaction Kinetics	247	67	Adverse Drug Reactions	1330
19	Disperse Systems	257	68	Pharmacogenetics	. 1344
20	Rheology	310	69	Pharmacological Aspects of Drug Abuse	1349
			70	Introduction of New Drugs	1365
	Part 3 Pharmaceutical Chemistry				
				Part 7 Diological Products	
21	Inorganic Pharmaceutical Chemistry	329		. •	
22	Organic Pharmaceutical Chemistry	356	71	Principles of Immunology	1379
23	Natural Products	380	72	Immunizing Agents and Diagnostic Skin	
24	Drug Nomenclature—United States Adopted			Antigens	1389
	Names	412	73	Allergenic Extracts	1405
25	Structure-Activity Relationship and Drug	400	74	Biotechnology and Drugs	1416
	Design	422			
				Part 8 Pharmaceutical Preparations and The	PÎF
	Part 4 Testing and Analysis			Manufacture	
26	Analysis of Medicinals	435	75	Preformulation	1435
27	Biological Testing	484	76	Biografiability and Bioequivalency Testing	1451
28	Clinical Analysis	495	77	Separation	1459
29	Chromatography	529	78	Sterilization	1470
30	Instrumental Methods of Analysis	555	79	Tonicity, Osmoticity, Osmolality and Osmolarity	1481
31	Dissolution	589	80	Plastic Packaging Materials	1499
	,		81	Stability of Pharmaceutical Products	1504
n.	art 5 Radioisotopes in Pharmacy and Medic	ioc	82	Quality Assurance and Control	1513
P	irr 5 Macioisotopes in Pharmacy and Medic	me	83	Solutions, Emulsions, Suspensions and	
32	Fundamentals of Radioisotopes	605		Extractives	1519
33	Medical Applications of Radioisotopes	624	84	Parenteral Preparations	1545
			85	Intravenous Admixtures	1570
	Base 6 Bhaumanniad and Madisias Asses	4	86	Ophthalmic Preparations	1581
	Part 6 Pharmaceutical and Medicinal Agent	rs	87	Medicated Applications	1596
34	Diseases: Manifestations and Patho-		88	Powders	1615
	physiology	655	89	Oral Solid Dosage Forms	1633
35	Drug Absorption, Action and Disposition	697	90	Coating of Pharmaceutical Dosage Forms	1666
36	Basic Pharmacokinetics	725	91	Sustained-Release Drug Delivery Systems	1676
37	Clinical Pharmacokinetics	746	92	Aerosols	1694
38	Topical Drugs	757			
39	Gastrointestinal Drugs	774		Part 9 Pharmaceutical Practice	
40	Blood, Fluids, Electrolytes and Hematologic	- • •		. WILL FIMILIATE VILLE FIGURE	
	Drugs	800	93	Ambulatory Patient Care	1715
41	Cardiovascular Drugs	831	94	Institutional Patient Care	1737
42	Respiratory Drugs	860	95	Long-Term Care Facilities	1758
43	Sympathomimetic Drugs	870	96	The Pharmacist and Public Health	1773



97	The Patient: Behavioral Determinants	1788	106	Poison Control	1905
98	Patient Communication	1796	107	Laws Governing Pharmacy	1914
99	Drug Education	1803	108	Community Pharmacy Economics and	
100	Patient Compliance	1813		Management	1940
101	The Prescription	1828	109	Dental Services	1957
102	Drug Interactions	1842			
103	Clinical Drug Literature	1859		Index	
104	Health Accessories	1864			
405	Surgical Supplies	4805		Alphobetic Index	4067



Sustained-Release Drug Delivery Systems

Mark A Longer, PhD

MRC Research Fellow Department of Biological Sciences University of Keele Keele, Staffordshire STS 5BG England

The goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site in the body to achieve promptly, and then maintain, the desired drug concentration. This idealized objective points to the two aspects most important to drug delivery, namely, spatial placement and temporal delivery of a drug. Spatial placement relates to targeting a drug to a specific organ or tissue, while temporal delivery refers to controlling the rate of drug delivery to the target tissue. An appropriately designed sustained-release drug delivery system can be a major advance toward solving these two problems. It is for this reason that the science and technology responsible for development of sustained-release pharmaceuticals have been and continue to be the focus of a great deal of attention in both

Joseph R Robinson, PhD

Professor of Pharmacy School of Pharmacy University of Wisconsin Modison, WI 53706

industrial and academic laboratories. There currently exist numerous products on the market formulated for both oral and parenteral routes of administration that claim sustained or controlled drug delivery. The bulk of research has been directed at oral dosage forms that satisfy the temporal aspect of drug delivery, but many of the newer approaches under investigation may allow for spatial placement as well. This chapter will define and explain the nature of sustained-release drug therapy, briefly outline relevant physicochemical and biological properties of a drug that affect sustained-release performance and review the more common types of oral and parenteral sustained-release dosage forms. In addition, a brief discussion of some methods currently being used to develop targeted delivery systems will be presented.

Conventional Drug Therapy

To gain an appreciation for the value of sustained drug therapy it is useful to review some fundamental aspects of conventional drug delivery.1 Consider single dosing of a hypothetical drug that follows a simple one-compartment pharmacokinetic model for disposition. Depending on the route of administration, a conventional dosage form of the drug, eg, a solution, suspension, capsule, tablet, etc, probably will produce a drug blood level versus time profile similar to that shown in Fig 91-1. The term "drug blood level" refers to the concentration of drug in blood or plasma, but the concentration in any tissue could be plotted on the ordinate. It can be seen from this figure that administration of a drug by either intravenous injection or an extravascular route, eg, orally, intramuscularly or rectally, does not maintain drug blood levels within the therapeutic range for extended periods of time. The short duration of action is due to the inability of conventional dosage forms to control temporal delivery. If an attempt is made to maintain drug blood levels in the therapeutic range for longer periods by, for example, increasing the dose of an intravenous injection, as shown by the dotted line in the figure, toxic levels may be produced at early times. This obviously is undesirable and the approach therefore is unsuitable. An alternate approach is to administer the drug repetitively using a constant dosing interval, as in multiple-dose therapy. This is shown in Fig 91-2 for the oral route. In this case the drug blood level reached and the time required to reach that level depend on the dose and the dosing interval. There are several potential problems inherent in multiple-dose therapy.

- If the dosing interval is not appropriate for the biological halflife of the drug, large "peaks" and "valleys" in the drug blood level may result. For example, drugs with short half-lives require frequent dosings to maintain constant therapeutic levels.
- The drug blood level may not be within the therapeutic range at sufficiently early times, an important consideration for certain disease states.
- 3. Patient noncompliance with the multiple-dosing regimen can result in failure of this approach.




Fig 91-1. Typical drug blood level versus time profiles for intravenous injections and an extravascular route of administration.




Fig 91-2. Typical drug blood level versus time profile following oral multiple-dose therapy.



1676

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

